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FASA I DAN FASA II METABOLISME DRUG MITRAGYNINE DALAM 
TIKUS NORMAL DAN YANG DIARUH DIABETES 
 
ABSTRAK 
Mitragynine ialah alkaloid indol utama yang kebanyakannya  diasingkan daripada 
daun M. speciosa. Mitragynine mempamerkan kesan depresan seperti morfina dan 
kesan perangsang seperti kokain. Mitragynine juga menunjukkan kesan seperti 
antitusif dan antidepresan. Penyelidikan ini dijalankan untuk menilai kesan 
mitragynine secara in vitro dan in vivo pada fasa I dan fasa II enzim metabolisme 
drug, iaitu aminopyrine N-demethylase (APND), UDP-glukuronosil transferase 
(UGT) dan glutation S-transferase (GST) dalam hati tikus Sprague-Dawley (SD). 
Kesan in vitro mitragynine pada aktiviti APND dibawah pengaruh umur, jantina dan 
penyakit telah  ditentukan dalam hepatosit tikus. Selain itu, mekanisme yang 
mungkin untuk induksi aktiviti aminopyrine N-demethylase oleh mitragynine juga 
dikaji pada hepatosit tikus SD jantan dan betina. Analisis blot western telah 
dilakukan bagi enzim fasa I  (CYP2C12) dan enzim fasa II (UGT1A6 dan GSTM1) 
untuk ekspresi protein dalam tikus normal dan tikus diabetik. Aminopyrine, p-
nitrofenol dan 1-kloro-2,4-dinitro benzena telah digunakan sebagai substrat prob 
untuk menentukan aktiviti APND, UGT dan GST masing-masing. Dalam kajian in 
vitro, satu julat kepekatan mitragynine (0.0025 - 250 μM) telah digunakan untuk 
semua ujian enzim pada kumpulan tikus SD yang diuji. Dos oral mitragynine 50 mg 
/kg berat badan  telah diberikan kepada tikus SD mengikut tempoh rawatan untuk 
kajian in vivo. Keputusan daripada  kajian in vitro menunjukkan bahawa 
mitragynine meningkatkan aktiviti APND dengan signifikan (p < 0.05) dalam 
hepatosit tikus. Ia juga merencat aktiviti UGT dalam mikrosom dan aktiviti sitosolik 
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GST dengan signifikan dalam tikus biasa dan tikus diabetik. Secara  in vitro 
perencatan  aktiviti enzim UGT dan GST  adalah kurang daripada 70% oleh itu nilai 
untuk IC50 mitragynine tidak dapat ditentukan. Keputusan daripada kajian in vivo 
menunjukkan bahawa rawatan sub-kronik mitragynine menginduksi aktiviti  APND, 
UGT dan GST dengan signifikan (p < 0.05) pada tikus biasa dan tikus diabetik. 
Mekanisme yang mungkin untuk kesan induksi daripada mitragynine ke atas 
metabolisme aminopyrine dalam hepatosit tikus SD jantan dan betina  adalah 
mungkin melalui perencatan G-protein, protein kinase A, protein kinase G dan 
tyrosine kinase dalam laluan cAMP. Tambahan lagi, analisis Western blot untuk 
ekspresi protein CYP2C12, UGT1A6 dan GSTM1 dalam tikus normal dan tikus 
diabetik yang dirawat dengan mitragynine (50 mg/kg selama 14 hari) menunjukkan 
peningkatan yang signifikan. Kesimpulan daripada kajian ini menunjukan bahawa 
pengambilan  mitragynine secara sub-kronik membawa kepada peningkatan aktiviti 
enzim metabolisme drug dan paras protein. Faktor jantina dan penyakit  tidak 
mempunyai pengaruh ke atas aktiviti APND, UGT dan GST secara in vitro dengan 
kehadiran mitragynine. Kemungkinan wujud bahawa mitragynine boleh berinteraksi 
dengan ubat-ubatan yang merupakan substrat kepada enzim N-demethylase dan 
UGT1A6. 
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PHASE I AND PHASE II DRUG METABOLISM STUDY OF 
MITRAGYNINE IN NORMAL AND DIABETES INDUCED RAT 
ABSTRACT 
 
         Mitragynine is a major indole alkaloid abundantly isolated from M. speciosa 
leaves. Mitragynine exhibits psychoactive properties and shows morphine-like 
depressant effect and cocaine-like stimulant effects. Mitragynine also shows 
antitussive and antidepressant-like effects. The current research was undertaken to 
evaluate the in vitro and in vivo effect of mitragynine on phase I and phase II drug 
metabolizing enzymes, namely aminopyrine N-demethylase (APND), UDP-
glucuronosyl transferase (UGT) and glutathione S-transferase (GST) in normal and 
diabetes  Sprague-Dawley (SD) rat liver. The in vitro effect of mitragynine on APND 
activity in relation to factors of age, gender and diabetes was determined in rat 
hepatocytes. Moreover, the possible mechanism of induction of aminopyrine N-
demethylase activity by mitragynine was also investigated in SD rat hepatocytes. In 
addition, western blot analysis was carried out for in vivo CYP2C12 and UGT1A6 
and GSTM1 proteins expression in normal and diabetic rats. Aminopyrine, p-
nitrophenol and 1-chloro-2,4-dinitro benzene were used as a probes to determine the 
APND, UGT and GST activity respectively. A range of mitragynine concentration 
(0.0025 – 250 µM) was used for all in vitro enzyme assays in tested groups of SD 
rats. The mitragynine 50 mg/kg of body weight was administered orally to SD rats 
for in vivo study. Results of in vitro study showed that mitragynine significantly (p < 
0.05) enhanced APND activity in rat hepatocytes as well as significantly inhibited 
microsomal UGT and cytosolic GST activity in normal and diabetic rats. In vitro 
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inhibition of UGT and GST enzyme activity was less than 70% and the IC50 values 
for mitragynine could not be determined. In vivo study showed that sub-chronic 
treatment of mitragynine significantly (p < 0.05) induced APND, UGT and GST 
activity in normal and diabetic rats. The possible mechanism of the induction effect 
of mitragynine on aminopyrine metabolism in male and female SD rat hepatocytes 
was probably mediated through inhibition of G-protein, protein kinase A, protein 
kinase G and tyrosine kinase in cAMP pathway. Furthermore, Western blot analysis 
showed that mitragynine increased significantly the CYP2C12, UGT1A6 and 
GSTM1 proteins level in mitragynine (50 mg/kg for 14 days) treated normal and 
diabetic rat livers. It is concluded from the present study that sub-chronic 
administration of mitragynine to normal and diabetic rats leads to enhanced hepatic 
drug metabolizing enzymes activities as well as their proteins level. The gender, age 
and disease factors have no influence on APND, UGT and GST activity in vitro in 
the presence of mitragynine. A possibility exists that mitragynine can interact with 
drugs which are substrates for N-demethylase and UGT1A6 enzyme. 
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CHAPTER 1 
INTRODUCTION 
Mitragynine is an important and major alkaloid derived from Mitragyna speciosa 
leaves. Mitragyna speciosa (M. speciosa) plant belongs to family Rubiaceae and is 
found in tropical and subtropical regions of Asia. M. speciosa has been traditionally 
used to treat opioid withdrawal symptoms, as an antipyretic and an analgesic. 
Additionally, it was also observed that Malaysian people consumed M. speciosa 
leaves as an opium substitute (Burkill, 1935). Chronic use of M. speciosa develops 
tolerance (Suwanlert, 1975; Pasternak, 2001) perhaps; withdrawal symptoms are 
less intensive than morphine (Vicknasingam et al., 2010). Mitragynine was isolated 
from M. speciosa leaves in 1921 (Tsuchiya et al., 2002) and is responsible for most 
of the plant’s pharmacological effects. A study has described the psychoactive 
properties of mitragynine and quoted that mitragynine can minimize opioid 
withdrawal syndrome (Jansen and Prast, 1988). Mitragynine produces analgesia by 
acting on mu (µ) and delta (δ) opioid receptors (Takayama et al., 2002). Opioid 
receptors are responsible for euphoria, analgesia and dependence. Mitragynine 
received wide attention by researchers due to its morphine-like depressant and 
cocaine-like stimulant effects. Different studies have shown that mitragynine 
exhibited antidepressant, antihypertensive, antitussive, antidiarrheal, smooth muscle 
relaxant and anti-inflammatory activities (Grewal, 1932; Matsumoto, 1996; 
Watanabe et al., 1997; Idayu et al., 2011). Furthermore, it also exhibits morphine- 
like effects on gastric acid secretion (Matsumoto et al., 2005) and inhibition of 2-
deoxy-D-glucose-stimulated gastric acid secretion in rats (Tsuchiya et al., 2002). 
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Most of the previous studies on mitragynine were focused on its behavioral, 
cognitive, central nervous system effects, antinociceptive action and receptors 
involved to cause analgesia. There are some unresolved issues regarding the effect 
of mitragynine on drug metabolism including its effects on CYP450, UDP-
glucuronosyltransferase and glutathione S-transferase enzymes. Efficacy and safety 
are important elements during drug or an herbal drug development and mainly 
depend on drug metabolism studies. It is essential to evaluate type of enzymes 
involved and how a candidate drug is being metabolized.  
            Herbal derived compounds are usually administered orally and acquire 
moderate to high concentration in the liver. The modulation of hepatic enzymes by 
herbal derived compounds serve as a potentially important mechanism by which the 
bioavailability of co-administered drug can be changed (Zhou et al., 2009). The 
superfamily CYP450 (CYP450) enzymes is partly responsible for metabolism of 
xenobiotics including: drugs, carcinogens, pollutants and steroids (Zhou et al., 
2004). Several reports have been published regarding pharmacokinetic interaction 
that develops between natural compounds/ herbal products and western drugs used 
clinically simultaneously (Budzinski et al., 2000; Foster et al., 2003; Strandell et al., 
2004). The alteration of drug metabolism by concomitant use of herbal medicines is 
significantly important. Most of the clinical adverse reactions are considered to be 
due to drug interactions responsible for the induction or inhibition of the drug-
metabolizing enzymes (Woolf, 1999; Izzo, 2004). CYP450 inhibition usually 
develops rapidly, even after a single dose of inhibitor (Pelkonen et al., 1998; Cott, 
2001). Enzyme inhibition decreases the metabolism of co-administered drug and 
enhances the plasma drug concentration. Subsequently, life threatening 
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circumstances may develop and lead to toxicity. For example, terfenadine (enzyme 
inhibitors) caused severe toxicity due to inhibition of CYP3A4 and has been 
withdrawn from the market due to its high possibility of drug-drug/herb interactions 
(Gottlieb, 1999). On the contrary to enzyme inhibition, CYP450 induction resulted 
in an increased synthesis of enzyme proteins. Enzyme induction by herbs depends 
upon the dose, duration and route of administration (Cott, 2001; Zhou et al., 2003). 
For example, St John’s wort induced intestinal and hepatic CYP3A4 after two weeks 
of administration but short term administration had no effect on CYP3A4 activity 
(Wang et al., 2001). Subsequently, enzyme induction enhances the hepatic 
metabolism of those co-administered drugs that are metabolized by induced 
enzymes and plasma concentration of drug decreases with loss of efficacy (Lin and 
Lu, 1998). For instance, rifampicin (an enzyme inducer) can greatly decrease the 
plasma concentrations of triazolam and abolishes its effect (Villikka et al., 1997). 
           The propensity to cause herb-drug interactions when they are co-administered 
by herbs triggers the importance to study the potential interaction between modern 
drugs and herbs or herb derived compounds. To date, no study has been carried out 
to determine the in vitro and in vivo effects of mitragynine on phase I and phase II 
drug metabolism in relation to factors of age, gender and disease in Sprague Dawley 
(SD) rat hepatocytes. The main objective of this study is to identify the existence of 
possible undesirable interaction effects of mitragynine on CYP450, UDP-
glucuronosyltransferase (UGT) and glutathione S-transferase (GST) activity as well 
as to evaluate possible mechanism involve in this interaction. Moreover, the extent 
of in vivo sub-chronic effect of mitragynine on phase I and phase II drug 
metabolizing enzymes expression will be evaluated by Western blot analysis. To 
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evaluate the magnitude of phase I and    phase II enzymes induction or inhibition by 
mitragynine, rat hepatocytes and liver subcellular fractions were used. For in vitro 
drug metabolism studies, a range of mitragynine concentrations (0.0025 – 250 µM) 
were used. For in vivo studies, mitragynine at 50 mg/kg of body weight will be 
orally fed to normal and diabetes induced SD rats. 
 
1.1 Objectives of the Study 
The aims of the study are: 
i. To study the in vitro and in vivo effect of mitragynine on phases I metabolizing 
enzyme (aminopyrine N-demethylase) in different groups of rat hepatocytes. 
ii. To study the in vitro and in vivo effect of mitragynine on phase II metabolizing 
enzymes, UDP-glucuronosyltransferase (UGT) and glutathione S-transferase (GST) 
using different groups of rat liver samples. 
iii. To evaluate the possible molecular mechanism pathway involved in the effect of 
mitragynine on aminopyrine metabolism in rat hepatocytes in vitro. 
iv.  To investigate in vivo protein expression by Western blotting in normal and 
diabetic rat livers.  
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                           Chart 1.1: Experimental Design for the In Vitro Effect of Mitragynine on Aminopyrine N-demethylase (APND), UDP-
glucuronosyltransferase (UGT), and Glutathione S-transferase (GST) activity in rat liver 
 
 
 
 
 
 
 
 
 
 
 
  
  
Female  Male  
Diabetic SD rat Normal SD rat 
Serial dilutions of mitragynine were used: 
0.0025, 0.025, 0.25, 2.5, 25 and 250 µM 
In vitro Phase I APND study            
(to find most affected group of rats) 
 
Old Adult Adult 
Male  Female  
Old 
In vitro Phase II UGT, GST study          
(only for most affected groups of rats) 
Normal SD rat Diabetic SD rat 
Adult female Adult male Adult male Adult female 
Possible molecular mechanism involved in effect of mitragynine 
on APND activity in hepatocytes (Gibson & Skett, 1994) 
 
Preparation of rat liver samples 
UGT assay 
(Habig et al., 1974)   
GST assay         
(Bock & Kohle, 2004) 
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                   Chart 1.2:  Experimental Design for the In Vivo Effect of Mitragynine on Aminopyrine N-demethylase (APND), UDP-
glucuronosyltransferase (UGT), and Glutathione S-transferase (GST) activity in rat liver 
 
 
                               
                                                                                                                                                                                                      
 
 
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
Sub-chronic (14 days treatment) Acute (single oral dose) 
50 mg/kg of mitragynine was fed 
Normal male SD rat Diabetic male SD rat 
Microsomes 
 
Cytosolic fraction 
 
Western Blotting for specific 
enzymes proteins expression 
Preparation of rat liver samples 
GST assay  UGT assay  
CYP2C12 
UGT1A6 
Cytosolic fraction 
 
Microsomes 
 
APND assay
     
GSTM1 
In vivo Phase I & phase II hepatic drug metabolism study (for the most affected groups) 
Hepatocytes 
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9CHAPTER 2 
INTRODUCTION AND LITERATURE REVIEW 
 
2.1 Herbal Medicines 
          Traditional, alternative and complementary medicines are commonly used to 
treat illness or prevent chronic disease within local or regional healing practices and 
to improve quality of life. A herb or its parts are often used for flavor, scent or 
therapeutic value. According to Encyclopedia of Britannica, herbal medicine is also 
called phytomedicine or botanical medicine, are used as dietary supplement and for 
primary health care. Different part of herbal plant such as plant's seeds, flowers, 
berries, leaves,  roots or bark are used for medicinal purposes. According to World 
Health Organization (WHO) definition, herbal medicines are herbs, herbal 
preparations, herbal materials, and finished herbal products. These herbal medicines 
may contain active ingredients from a single plant or may be a combination of more 
than one plant. Herbs and plants can be taken in different ways and forms, and they 
include the whole herb, teas, syrup, essential oils, ointments, capsules and tablets 
that contain a ground or powdered form of a raw herb or its dried extract. 
The global popularity of herbal drugs and supplements has caused a 
remarkable interest in understanding the basis of the biological activity of traditional 
medicines. Traditional medicines have different system of practice, the practice and 
philosophy of each system is influenced by the customary conditions, geographic 
area and environment within which it first works out (WHO, 2005). Traditional 
Chinese medicine (TCM) is an influential example of how ancient knowledge is 
applied in a holistic way to treat health problems. TCM is more than 3000 years old 
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(Xutian et al., 2009) and is a flourishing practice around the world and is used for 
preventing and treating diseases. Three of the top-selling herbal products, namely 
Allium sativum (garlic), Ginkgo biloba and Panax ginseng, can be detected in TCM 
and are nowadays used to treat various ailments (Li et al., 2008). 
There are certain factors that determine the high interest towards natural 
medicine, such as cost, adverse effects of allopathic drugs and lack of treatment in 
the many chronic diseases such as arthritis, diabetes, cancer and cardiac problems 
and in the infectious type diseases (HIV and hepatitis). Furthermore, traditional 
medicines are comparatively perceived as natural and without adverse effects, or not 
toxic. This is not compulsorily true, particularly when herbs are administered with 
other herbs or prescription drugs, as is very common (Canter and Ernst 2004; Loya 
et al., 2009). Currently, herbs are used to treat acute and chronic conditions of 
disease and treat problems such as prostate problems, inflammation, and depression 
and to boost the immune system. In China, herbal medicines played a dominant role 
in the strategy to treat severe acute respiratory syndrome (SARS) (WHO, 2003). 
Moreover, in Africa, the Africa flower, a traditional herbal medicine has been used 
to treat symptoms associated with HIV (Tilburt and Kaptchuk, 2008).  
About 200 years ago, morphine was first extracted from seeds pod of                    
Papaver somniferum and it has been administered in precise dosage forms up till 
now (Rousseaux and Schachter, 2003). Other novel examples include the cardiac 
stimulant digoxin from Digitalis purpurea, salicylic acid that is an origin of aspirin, 
isolated from willow bark, an antipsychotic and antihypertensive drug reserpine 
from Rauwolfia serpentina, antimalarial quinine, from Cinchona bark, antibiotics 
erythromycin, penicillin and lipid-lowering agents lovastatin from  fungus (Rishton, 
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2008; Schmidt and Ribnicky, 2008). Worldwide, 70% of cancer drugs approved for 
treatment are derived from natural products. Cancer therapeutics derived from plants 
is paclitaxel, isolated from the Pacific yew tree and vinca alkaloids from 
Catharanthus roseus (Brower, 2008). 
There are 252 drugs in the WHO essential medicine list and out of these 11% are of 
plant origin (Sahoo et al., 2010). Additionally, the WHO estimates that 80% of the 
population of some Asian and African countries utilizes herbal medicine for primary 
health care and the worldwide annual market for these products can reach US$ 60 
billion (WHO, 2002). In the past, there has been renewed attention and interest in 
the use of traditional medicine globally. In Malaysia, traditional medicines have 
been used for centuries. However, this system is influenced by Chinese, Indonesian 
and Indian tradition (Zakaria and Mohd, 1994). It was reported in 1999 that 
Malaysian market for medicinal and herbal products together with aromatic plants 
was estimated 4.6 billion and the average annual growth was 15 – 20% (Jamal, 
2006). In Malaysian peninsular region, 1,300 medicinal plant species were recorded 
(Burkill, 1966).  
According to a WHO report, Malaysia is one of the nine countries that bestowed a 
large amount of herbal sales worldwide between the year of 1999 to 2001 (WHO, 
2005). Moreover, the Malaysian market for natural and herbal products was 
estimated to cost approximately RM10 billion in 2008 and showed continuously 
increase at the rate of 8% per year. Hence, it is predicted that by 2050, the 
Malaysian market for these products would be 5 US trillion dollars (Ahmad, 2010). 
Examples of important Malaysian medicinal plants are Labisia pumila (Kacip 
Fatimah), Eurycoma longifolia Jack (Tongkat Ali), Ficus deltoidea (Mas cotek), and 
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Piper sarmentosum (Daun kaduk). These herbs have antioxidant, antibacterial, 
antipyretic, antitumor and anti-inflammatory activities (Zakaria and Mohd, 1994; 
Bhat and Karim, 2010; Zakaria et al., 2010). 
2.2 Literature review of Mitragyna speciosa Korth and Mitragynine 
2.2.1 Mitragyna speciosa Korth 
           In recent years, a new herbal drug that has appeared on the drug scene in 
Malaysia is Mitragyna speciosa (M. speciosa) which has a strong abuse potential 
and has been used for its opiate-like effects (Maurer, 2010). M. speciosa belongs to 
the family of Rubiaceae. It is found in tropical and subtropical regions of Asia. 
2.2.1.1 Habitat 
          M. speciosa is indigenous to Malaysia, Thailand, Cambodia, East and West 
Africa and in India (Harvala, 1988). It is called ketum in Malaysia and kratom in 
Thailand (Shellard, 1978). In Malaysia and Thailand two varieties of M. speciosa 
are found, one plant contains red vein in the leaf and the other has green vein in its 
leaf. It is assumed that red vein variety possesses more potent biological activities 
than green vein plant (Chittrakarn et al., 2007). 
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Figure 2.1: Mitragyna speciosa Korth  
The taxonomy of Mitragyna speciosa is: 
            Class: Plantae 
             Subclass: Magnoliophyta 
             Order: Gentianales 
             Family: Rubiaceae 
             Genus: Mitragyna 
             Species: Speciosa 
             Scientific name: Mitragyna speciosa Korth 
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2.2.1.2 Folk Usage 
            In Malaysia and Thailand the leaves of M. speciosa are often chewed, 
smoked or consumed as tea. In Thailand, kratom users focused on the perceived 
advantages in relation to increased work stamina and as medication rather than its 
harmful effects (Sawitri, 2007). Kratom have been reported to be a central nervous 
system stimulant. It also helps to increase work efficiency and tolerance to hard 
work under a burning sun (Suwanlert, 1975). Moreover, chronic exposure by human 
leads to withdrawal symptoms including yawning, myalgias, diarrhea and rhinorrhea 
(Suwanlert, 1975).  In Malaysian folk medicine, the leaves are used to treat diarrhea, 
fever, as cough suppressant in asthma, antihypertensive, anti-inflammatory, pain 
killer and as substitute for opium or morphine in the treatment of drug addicts    
(Reanmongkol et al., 2007). 
2.2.1.3 Pharmacological studies 
            The use of ketum as self-management of opioid withdrawal is increasing 
without proper scientific bases and is currently leading to its wide abuse. It is 
demonstrated that side effects and withdrawal symptoms such as craving, fatigue, 
insomnia and kidney complaints from ketum addiction are less intensive and less 
toxic than morphine (Vicknasingam et al., 2010). A number of pharmacological 
effects are evaluated by studies on aqueous, methanol and total alkaloid extracts of 
M. speciosa. Crude extract of M. speciosa has been reported that analgesic effect of 
extract was more pronounced than mitragynine (Watanabe et al., 1997). Methanol, 
aqueous and alkaloid extracts of M. speciosa exerted the antinociceptive response to 
hot plate and tail flick tests and was blocked with naloxone (Reanmongkol et al., 
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2007; Sabetghadam et al., 2010). The extract inhibited the twitch contraction in a 
concentration dependent manner and had inhibitory effects on the rat gastrointestinal 
tract and therefore it could be used as antidiarrheal agent (Chittrakarn et al., 2007; 
Chittrakarn et al., 2010).  
         Alkaloid and aqueous extracts of M. speciosa have shown antidepressant-like 
(Kumarnsit et al., 2007). Moreover, the methanol extract of M. Speciosa showed 
antiinflammatory effect (Mossadeq et al., 2009) and GST specific activity inhibition 
in rat (Azizi et al., 2010). Subsequently, ethanol extract of M.speciosa leaves caused  
inhibition of CYP2D6 and CYP3A4 isoforms of human CYP450 (Hanapi et al., 
2010). The LD50 values of the alkaloid and methanol extracts of M. speciosa in mice 
were 173.20 mg/kg and 4.90 g/kg respectively after oral administration. In addition, 
acute toxicity signs with M. speciosa extracts were tremor, lethargy, paralysis, 
apnea, tonic- clonic convulsions (Reanmongkol et al., 2007). High dose 1000 mg/kg 
of standardized methanol extract of M. speciosa leads to nephrotoxicity and 
hepatotoxicity in rat (Harizal et al., 2010). A rare case of M. speciosa exposure 
toxicity was reported and confirmed by urinary analysis of mitragynine (Nelson et 
al., 2010). 
            More than 25 alkaloids have been isolated from M. speciosa leaves. The 
main constituents are mitragynine, speciogynine, 7-hydroxymitragynine, 
paynanthein and speciocilitine. Out of these mitragynine is the major constituent i.e. 
66.2% (Takayama, 2004). The molecular structures of main alkaloids of M. speciosa 
are shown in Figure 2.2. 
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Figure 2.2: Molecular Structure of Important Alkaloids of M. speciosa.                  
(a) Mitragynine and (b) 7-hydroxymitragynine.  
 
 
 
 
(b) 
(a) 
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2.2.2 Mitragynine 
               Mitragynine is the most abundant active indole alkaloid isolated from M. 
speciosa leaves. Mitragynine was first isolated in 1907 by Hooper.  The isolation 
was repeated again by Field (Tsuchiya et al., 2002) and gave the alkaloid its name. 
Its molecular structure C23H30N2O4 was fully determined by Zacharis et al., 1964. 
The first total synthesis of (-)-mitragynine in the optically pure form was done in 
1995 (Takayama et al., 1995). Its molecular weight is 398.5.  It is poorly soluble in 
water and soluble in alcohol, acetic acid and chloroform (Janchawee et al., 2007; 
Babu et al., 2008; Parthasarathy et al., 2013). The pharmacology and chemistry of 
mitragynine have been investigated since the early twentieth century. 
2.2.2.1 Pharmacological Studies  
            In 1932, Grewal reported the pharmacology of mitragynine (Grewal, 1932). 
The study concluded that mitragynine exhibited antiprotozoal, intestinal smooth 
muscle relaxant, antihypertensive, antitussive and cellular oxidation inhibiting 
activities.  
I. Receptor Affinity 
            Mitragynine is a full opioid agonist and has a high binding selectivity for µ-
opioid receptors (Ma et al., 2007) and δ- opioid receptors (Yamamoto et al., 1999; 
Takayama et al., 2002). Pharmacologically, µ-opioid receptors comprised of three 
subtypes µ1, µ2 and µ3-opioid receptors. The µ1 –receptors are responsible only for 
analgesia while µ2 –receptors produce respiratory depression, gastro intestinal transit 
and itching in addition to analgesia. Both µ1, µ2 -opioid receptors both are found in 
brain, spinal cord and periphery. The µ3-opioid receptors are located in periphery 
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(Dietis et al., 2011). It has dual action; at lower doses, mitragynine is shown to act 
on descending noradrenergic and serotonergic receptors while at higher doses it acts 
on supraspinal µ- and delta δ-opioid receptors. The µ-opiate receptors are 
responsible for euphoria, analgesia and physical dependence. Descending 
noradrenergic and serotonergic systems were found to contribute towards the 
antinociceptive activity of mitragynine on mechanical noxious stimulation. Only 
descending noradrenergic system is involved for blocking thermal noxious 
stimulation by mitragynine (Watanabe and Matsumoto, 1996). Moreover, it has been 
reported that mitragynine stimulates post synaptic α2 receptors and inhibits 5-HT2A 
receptors (Matsumoto et al., 2005).  
II. Antinociceptive Effect 
Mitragynine has an antinociceptive activity and its action is dominantly 
mediated by µ- and δ- opioid receptors subtypes. It shows its activity when 
administered subcutaneously, orally, intravenously and intraperitoneally in rodents 
(Matsumoto, 1996). Mitragynine shows stronger analgesic effect and less respiratory 
depression and adverse effects than morphine (Watanabe et al., 1997; Matsumoto et 
al., 2008). 
III. Effects on gastrointestinal smooth muscles 
            Mitragynine inhibits 2-deoxy-D-glucose- stimulated gastric acid secretion in 
rats through opioid receptors (Tsuchiya et al., 2002). In addition to inhibition of 
gastric acid secretion it also inhibited the electrically stimulated contraction of 
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guinea pig ileum through opioid receptors and did not block any effect on smooth 
muscle contraction by acetylcholine or histamine (Watanabe et al., 1997). 
IV. Hypothermia 
      It was reported that mitragynine causes hypothermia in animals in addition to 
opiate-like effect (Jansen and Prast, 1988).  
V. Effect on glucose transport 
            Mitragynine exhibits insulin –like effect and enhances the glucose transport 
in muscle cells. However this effect with M. speciosa extract is more pronounced 
suggesting that other constituents of plant together with mitragynine contribute this 
effect (Purintrapiban, 2011). 
VI. Behavioral effect 
Mitragynine (1 mg/kg – 30 mg/kg, i.p) inhibited the locomotor activity of the rat. 
This result suggested that mitragynine has sedative properties (Moklas et al., 2008). 
In addition, chronic administration of mitragynine significantly impaired the 
cognitive function in mice (Apryani et al., 2010). Moreover, mitragynine (5 mg/kg – 
30 mg/kg, i.p) brought into play an antidepressant-like effect in tail suspension and 
forced swim test in mouse (Idayu et al., 2011). Acute oral administration of M. 
speciosa alkaloid extract and mitragynine in mice increased locomotion, rearing 
behaviour and reduced grooming time in a novel environment (Hazim et al., 2011). 
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VII. Pharmacokinetic studies 
            Mitragynine (50 mg/kg o.p; 1.5 mg/kg i.v) was administered to rat and its 
plasma concentration was determined.  Different parameters were estimated namely 
t1/2, AUC0-∞ and bioavailability. Mitragynine oral absorption was prolonged, slow 
and incomplete with 3.03% absolute bioavailability (Parthasarathy et al., 2010). 
Philipp and his colleagues (2009) identified mitragynine metabolites in human and 
rat urine. It was reported that mitragynine was metabolized by hydrolysis of 
methylester to the respective aldehyde, reduction to alcohol or by oxidation to 
carboxylic acids. In rat, four metabolites were conjugated to glucuronides and one 
conjugated to sulphate while in human three metabolites conjugated to glucuronides 
and three to sulphates (Philipp et al., 2009). Isomeric compounds of mitragynine 
have been detected in urines of kratom addicts by LC-MS (Philipp et al., 2011).  
LD50 value for the mitragynine has been reported i.e. 477 mg/kg after oral 
administration (Sabetghadam et al., 2012) and 126.7 mg/kg followed by 
intraperitonally route in mice (Watanabe et al., 1992).  
            To date, the effect of mitragynine on phase I and phase II drug metabolizing 
enzymes (DMEs) are not available. Hence the present study was designed to 
evaluate its effects in vitro and in vivo on DMEs and its propensity to cause drug – 
drug interaction. 
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2.3 Hepatic Drug Metabolism 
          Drug metabolism occurs in liver, kidney, lungs, intestines, brain and skin. 
Liver is the major organ of the body that plays a vital role in metabolism of 
endogenous compounds (steroids, hormones, fatty acids cholesterol and proteins) 
and exogenous substances (xenobiotics). Orally administered drugs absorbed in 
small intestine and reached in liver via portal vein where they are metabolized. In 
hepatocytes (liver cells) drug metabolizing enzymes are located in intracellular 
membrane of rough endoplasmic reticulum and in cytosol (Figure 2.3). Liver 
microsomes are located in the rough endoplasmic reticulum and contained a variety 
of drug metabolizing enzymes, most important are CYP450, (GSTs), 
sulphotransferases SULTs and UGTs. Drug metabolism is defined as the mechanism 
of biochemical degradation or modification of lipophilic drug that converts it into 
hydrophilic metabolites and enhance its elimination from the body. The drug 
metabolizing enzymes have a central role in drug metabolism, detoxification and 
elimination (Figure 2.4). 
          Drug metabolism occurs in two phases: phase I pathways a functionalization 
of drug molecules takes place in microsomes and phase II pathways are involved in 
conjugation reactions of phase I metabolites or parent compound in liver cytosol. As 
a result of drug metabolism, drugs can be activated, inactivated, detoxified and 
consequently their metabolites may be activated to enhance or inhibit the activity of 
the drug or become toxic leads in drug toxicity (Asha and Vidyavathi, 2009).  
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Figure 2.3: Histology of Liver (www.hopkins-gi.org) 
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Figure 2.4: Schematic diagram of drug metabolism pathways in hepatocytes. 
Proteins involve in metabolism are: Organic anion transport protein (OATP),    
Phase I includes CYP450, Phase II includes GSTs, UGTs, SULTs, Phase III 
includes export transporter, Multidrug resistance proteins (MRPs). Accumulation of 
reactive electrophilic metabolites leads to adduct formation with protein and DNA, 
and to initiation toxic responses. 
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2.3.1 Phase I Drug Metabolism Pathways (Functionalization Reactions) 
         The main phase I metabolism pathways are oxidation, reduction, hydrolysis 
and hydration. 
a) Oxidation Reactions 
        The microsomal mixed function-oxidase system (CYP450) is involved in drug 
oxidations. These reactions are carried out in the presence of CYP450 enzymes, 
NADPH-CYP450 reductase, molecular oxygen and lipid as shown in following 
reaction.  
NADPH H+ + O2 + RH                           NADP
+ + H2O + ROH 
           Where RH is an oxidisable drug and ROH is metabolite. Oxidation reactions 
involve insertion of one oxygen atom to the substrate, rearrangement of intermediate 
to form final product and the other oxygen atom is reduced to form water (Gibson 
and Skett, 2001).  
Here are some examples of drugs those are metabolized by specific oxidation 
reaction, Phenobarbital, phenytoin, aminopyrine, diazepam, codeine and lignocaine.  
           Another type of oxidation reactions are not catalyzed by CYP450 but 
catalyzed by non-microsomal oxidation enzymes. These reactions are more specific 
and are involved in endogenous compounds metabolism (Timbrell, 2000; Michael, 
2010). Oxidative enzymes are xanthine oxidases, aromatases, aldehyde and alcohol 
dehydrogenases, amine oxidases and alkylhydrazine oxidase. Histamine, 
catecholamines and imipramine adopt amine oxidation to metabolize. 
 
CYP450 
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b) Reduction reactions 
           Reduction reactions are catalyzed by hepatic microsomes. NADPH is an 
electron donor in reductive metabolism and oxygen is not required in these 
reactions. Examples of reactions are prontosil and  chloramphenicol (Michael, 2010; 
Gonzales, 2012).  
 
c) Hydrolysis reactions 
           Amides, carbamates, esters and hydrazides undergo hydrolysis reactions. 
Esterases and amidases are found in blood plasma as well as in liver and are 
responsible for catalyzing these reactions. Pethidine, procain, acetylsalicylic acid, 
indomethacin and isoniazid (Hernandez and Rathinavelu, 2006). 
d) Hydration reactions 
            Hydration is a special type of hydrolysis in which addition of water molecule 
to the substrate is carried out by epoxide hydrolase. Particularly polycyclic 
hydrocarbons (precarcinogenic) undergo this reaction to detoxify. 
 
2.3.2 Phase II Drug Metabolism Pathways (Conjugation Reactions) 
         After the phase I reactions drug changed into its metabolites which 
subsequently proceed to phase II metabolism. In phase II reactions, specific group is 
conjugated to the drug/drug metabolites leading formation of end product that 
comprise higher molecular weight and become more hydrophilic. In addition, this 
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conjugated moiety cannot reabsorb and gets excreted from the body through urine or 
bile (Timbrell, 2000). The principal phase II reactions are as follows:  
a) Glucuronidation 
          Glucuronidation is a commonly used pathway for conjugation reactions and 
most of the drugs and endogenous compounds are metabolized by the same 
pathway. UGT enzyme in the presence of co-factor UDP-glucuronic acid (UDPGA) 
catalyzes the conjugation of glucuronic acid to substrate.  
b) Glutathione conjugation 
           Many xenobiotics can be metabolized to toxic electrophilic compound by 
phase I metabolism. Glutathione (GSH) conjugates with electrophile in the presence 
of GST to non-toxic product. GST is located in hepatocytes cytosol. The compounds 
that undergo glutathione conjugation are epoxides, nitroalkanes, haloalkanes and 
aromatic compounds. Adriamycin and fosfomycin are drugs that utilize glutathione 
conjugation reaction (Gonzalez and Tukey, 2006). 
c) Sulfation 
Sulfation is the conjugation of PAPS with drug molecule and catalyzed by cytosolic 
enzyme SULTs. Acetaminophen, methyldopa and steroids are examples of drug 
undergo sulfation (Deshpande, 2002). 
 
 
